Abstract
Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 & IL-15 for a Shorter Duration Improves CAR T-Cell Immunophenotype While Maintaining Target Cell Dose
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have